Celldex Therapeutics (CLDX)
NASDAQ:CLDX
Want to see CLDX full AI Analyst Report?
CLDX Stock Chart & Stats
$34.55
-$0.90(-3.26%)
At close: 4:00 PM EST
$34.55
-$0.90(-3.26%)
Day’s Range― - ―
52-Week Range$19.52 - $35.79
Previous CloseN/A
Volume733.18K
Average Volume (3M)842.55K
Market Cap
$2.62B
Enterprise Value$2.16B
Total Cash (Recent Filing)$451.46M
Total Debt (Recent Filing)$1.91M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 06, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.27
Shares Outstanding78,492,070
10 Day Avg. Volume996,854
30 Day Avg. Volume842,553
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.63K
Enterprise Value/Gross Profit-18.41
Enterprise Value/Ebitda-7.70
Forecast
1Y Price Target
$51.10Price Target Upside47.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.35
Revenue Forecast (FY)$2.39M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthExtremely low leverage reduces refinancing and interest-rate risk, giving management flexibility to fund clinical programs or commercial rollouts. Over 2–6 months this balance-sheet cushioning materially lowers the probability of forced asset sales or distress financing while clinical milestones are pursued.
Recent ~$282M Equity Raise Strengthens FundingMaterial net proceeds provide durable runway to advance late-stage programs and prepare for potential commercialization. This reduces near-term liquidity risk and the immediate need for dilutive financings, enabling the company to execute development and launch activities over the next several quarters.
Focused Antibody / Bispecific Therapeutic PipelineA focused antibody and bispecific platform concentrates R&D expertise and can produce multiple asset opportunities from shared technology. If clinical readouts succeed, platform economics and repeatable development pathways can generate sustainable value beyond a single asset over the medium term.
Bears Say
High Cash Burn / Negative Cash FlowSustained large negative operating and free cash flow consumes capital and necessitates external funding for ongoing trials and commercialization prep. Over a multi-quarter horizon, this elevates execution risk if milestone success or fresh financing does not materialize, pressuring strategy and timelines.
Revenue Collapse And Deeply Negative ProfitabilityVery small, volatile revenue and extreme negative margins indicate the company lacks meaningful commercial cash generation. This structural unprofitability limits reinvestment capacity and makes long-term sustainability contingent on successful clinical outcomes or partner deals rather than internal cash flow.
Reliance On External Financing / Dilution RiskDependence on periodic equity raises exposes the company to market sentiment and dilutive financing cycles. Repeated capital raises can erode shareholder value and constrain long-term returns, while also forcing management to balance financing timing against clinical and commercial milestones.
Celldex News
CLDX FAQ
What was Celldex Therapeutics’s price range in the past 12 months?
Celldex Therapeutics lowest stock price was $19.52 and its highest was $35.79 in the past 12 months.
What is Celldex Therapeutics’s market cap?
Celldex Therapeutics’s market cap is $2.62B.
When is Celldex Therapeutics’s upcoming earnings report date?
Celldex Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 42 days.
How were Celldex Therapeutics’s earnings last quarter?
Celldex Therapeutics released its earnings results on May 07, 2026. The company reported -$1.18 earnings per share for the quarter, missing the consensus estimate of -$1.15 by -$0.03.
Is Celldex Therapeutics overvalued?
According to Wall Street analysts Celldex Therapeutics’s price is currently Undervalued.
Does Celldex Therapeutics pay dividends?
Celldex Therapeutics does not currently pay dividends.
What is Celldex Therapeutics’s EPS estimate?
Celldex Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does Celldex Therapeutics have?
Celldex Therapeutics has 78,492,070 shares outstanding.
What happened to Celldex Therapeutics’s price movement after its last earnings report?
Celldex Therapeutics reported an EPS of -$1.18 in its last earnings report, missing expectations of -$1.15. Following the earnings report the stock price went up 1.951%.
Which hedge fund is a major shareholder of Celldex Therapeutics?
Currently, no hedge funds are holding shares in CLDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celldex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.10 (47.90% Upside)
$51.10 (47.90% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 83.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.74%
12-Months-Change
Fundamentals
Return on Equity
-50.72%
Trailing 12-Months
Asset Growth
-30.86%
Trailing 12-Months
Company Description
Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
CLDX Stock 12 Month Forecast
Average Price Target
$51.10
▲(47.90% Upside)
Technical Analysis
Travere Therapeutics
―
Viridian Therapeutics
―
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Ownership Overview
0.13% Insiders
24.75% Mutual Funds
38.21% Other Institutional Investors
24.02% Public Companies and
Individual Investors